Neilsen PM - Search Results

1

In vitro cytotoxicity evaluation of thiourea derivatives bearing Salix sp. constituent against HK-1 cell lines.

Nordin NA, Lawai V, Ngaini Z, Abd Halim AN, Hwang SS, Linton RE, Lee BK, Neilsen PM. Nordin NA, et al. Among authors: neilsen pm. Nat Prod Res. 2020 Jun;34(11):1505-1514. doi: 10.1080/14786419.2018.1517120. Epub 2018 Dec 3. Nat Prod Res. 2020. PMID: 30507306

2

Nasopharyngeal carcinoma among the Bidayuh of Sarawak, Malaysia: History and risk factors.

Linton RE, Daker M, Khoo AS, Choo DCY, Viljoen M, Neilsen PM. Linton RE, et al. Among authors: neilsen pm. Oncol Lett. 2021 Jul;22(1):514. doi: 10.3892/ol.2021.12775. Epub 2021 May 6. Oncol Lett. 2021. PMID: 33986874 Free PMC article. Review.

3

p53 Represses the Oncogenic Sno-MiR-28 Derived from a SnoRNA.

Yu F, Bracken CP, Pillman KA, Lawrence DM, Goodall GJ, Callen DF, Neilsen PM. Yu F, et al. Among authors: neilsen pm. PLoS One. 2015 Jun 10;10(6):e0129190. doi: 10.1371/journal.pone.0129190. eCollection 2015. PLoS One. 2015. PMID: 26061048 Free PMC article.

4

Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy.

Pishas KI, Neuhaus SJ, Clayer MT, Adwal A, Brown MP, Evdokiou A, Callen DF, Neilsen PM. Pishas KI, et al. Among authors: neilsen pm. Oncol Rep. 2013 Jul;30(1):471-7. doi: 10.3892/or.2013.2454. Epub 2013 May 13. Oncol Rep. 2013. PMID: 23670273

5

Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ, Callen DF. Neilsen PM, et al. Oncogene. 2013 Jun 13;32(24):2992-3000. doi: 10.1038/onc.2012.305. Epub 2012 Jul 16. Oncogene. 2013. PMID: 22797073

6

The oncogenic role of miR-155 in breast cancer.

Mattiske S, Suetani RJ, Neilsen PM, Callen DF. Mattiske S, et al. Among authors: neilsen pm. Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1236-43. doi: 10.1158/1055-9965.EPI-12-0173. Epub 2012 Jun 26. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22736789 Review.

7

TAp63 regulates oncogenic miR-155 to mediate migration and tumour growth.

Mattiske S, Ho K, Noll JE, Neilsen PM, Callen DF, Suetani RJ. Mattiske S, et al. Among authors: neilsen pm. Oncotarget. 2013 Nov;4(11):1894-903. doi: 10.18632/oncotarget.1228. Oncotarget. 2013. PMID: 24177167 Free PMC article.

8

Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.

Shakya R, Tarulli GA, Sheng L, Lokman NA, Ricciardelli C, Pishas KI, Selinger CI, Kohonen-Corish MRJ, Cooper WA, Turner AG, Neilsen PM, Callen DF. Shakya R, et al. Among authors: neilsen pm. Oncogene. 2017 Aug;36(31):4469-4480. doi: 10.1038/onc.2017.66. Epub 2017 Apr 3. Oncogene. 2017. PMID: 28368395

9

Identification of ANKRD11 as a p53 coactivator.

Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF. Neilsen PM, et al. J Cell Sci. 2008 Nov 1;121(Pt 21):3541-52. doi: 10.1242/jcs.026351. Epub 2008 Oct 7. J Cell Sci. 2008. PMID: 18840648

10

Genome-wide mapping of ZNF652 promoter binding sites in breast cancer cells.

Kumar R, Selth LA, Schulz RB, Tay BS, Neilsen PM, Callen DF. Kumar R, et al. Among authors: neilsen pm. J Cell Biochem. 2011 Oct;112(10):2742-7. doi: 10.1002/jcb.23214. J Cell Biochem. 2011. PMID: 21678463

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page